

26 March 2025

Migraine Treatment

A. Please provide the number of migraine patients treated in the last 4 months with:

- **Atogepant (Aiquipta)**
- **Erenumab (Aimovig)**
- **Eptinezumab (Vyepiti)**
- **Fremanezumab (Ajovy)**
- **Galcanezumab (Emgality)**
- **Rimegepant (Vydura)**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin)**

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant (Aiquipta)	39	
·Erenumab (Aimovig)	0	
·Eptinezumab (Vyepiti)	0	
·Fremanezumab (Ajovy)	0	
·Galcanezumab (Emgality)	27	
·Rimegepant (Vydura)	n/a	6
·Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	127	

B. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**

10

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes